CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Zila Holding Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Zila Holding Inc
5227 North 7th Street
701 Centre Avenue
Phone: (302) 636-5400p:302 636-5400 WILMINGTON, DE  19808  United States Ticker: ZILAZILA
This company was Merged or Acquired on 9/18/2009.
This company ceased filing statements with the SEC on 9/18/2009.
Acquired by a subsidiary of TOLMAR Holding, Inc.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Zila, Inc. (Zila) is a diagnostic company focused on the prevention, detection and treatment of oral cancer and periodontal disease. Zila is a holding company that conducted its business operations, during the fiscal year ended July 31, 2008 (fiscal 2008), through its wholly owned subsidiaries, Zila Pharmaceuticals, Inc., Professional Dental Technologies, Inc. (Pro-Dentec), Zila Biotechnology, Inc., Zila Technical, Inc., Zila Limited and Ryker Dental of Kentucky, Inc. (inactive). The Company manufactures and markets ViziLite Plus with TBlue (ViziLite Plus), its principal product for the early detection of oral abnormalities that could lead to cancer. ViziLite Plus is an adjunctive medical device cleared by the United States Food and Drug Administration (FDA) for oral cancer. In September 2009, the Company announced the completion of the merger with a subsidiary of TOLMAR Holding, Inc. Pursuant to the merger, Zila has become a wholly owned subsidiary of TOLMAR Holding, Inc.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
4/30/20097/31/2008YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
3843 Dental equipment and supplies
7372 Prepackaged software
2833 Medicinal chemicals and botanical products
3651 Household audio and video equipment
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer David R.Bethune 68 9/18/2009 12/1/2005
Vice President - Finance, Treasurer Diane E.Klein 60 8/1/2007 8/1/2003
Vice President, General Counsel, Secretary Gary V.Klinefelter 60 10/1/2005 12/1/2004

Business Names
Business Name
Professional Dental Technologies, Inc.
ZILA
Zila Biotechnology, Inc
Zila Pharmaceuticals, Inc.
Zila Technical, Inc.
Zila, Inc.

General Information
Number of Employees: 296 (As of 11/30/2008)
Outstanding Shares: 10,407,763 (As of 4/30/2009)
Shareholders: 2,197
Stock Exchange: NASD
Federal Tax Id: 860619668
Email Address: zilapro@zila.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023